Infinia (alpha-1-antitrypsin)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- alpha-1-antitrypsin
- Company
- Kamada BioPharma Limited at Fieldfisher LLP
- Status
- Application withdrawn
- Therapeutic area
- Genetic Diseases, Inborn; Lung Diseases
- Designations
- Orphan
- Application
- EMEA/H/C/003934
- ATC
- B02AB02
- Official record
- www.ema.europa.eu
Indication
Treatment and maintenance therapy of adult patients with congenital deficiency of alpha-1 antitrypsin and lung disease with clinical evidence of emphysema and airway obstruction (FEV1/SVC<70%)
Regulatory milestones
No milestones recorded in the last year.
Follow Infinia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.